Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2451–2500 of 18397
On February 11, 2025, we announced that Joseph A. Ferraro, President and Chief Executive Officer, will transition to a Board Advisor role effective June 30, 2025.
the Board of Directors (the "Board") of the Company appointed Brian J. Choi, who has been serving as Chief Transformation Officer, as the Company's Chief Executive Officer ("CEO"), effective July 1, 2025.
On February 10, 2025, the Board elected Charles Smotherman, the Company's Senior Vice President, Chief Accounting Officer, as the Company's interim Chief Financial Officer, effective as of March 24, 2025
On February 7, 2025, Claire Bramley notified the Company of her decision to resign from her position as Chief Financial Officer of the Company (including as its principal financial officer and principal accounting officer) to take a Chief Financial Officer position with another company that is outside of the Company's industry.
Mr. Braunstein ceased to be President and Chief Executive Officer of the Company
Anders Edvell was appointed President and Chief Executive Officer of the Company
after which date Mr. Walker has been appointed and will begin serving as President and Chief Executive Officer of the Company
the previously reported retirement of Gregory S. Bielli, who has served in this capacity with the Company since December 2013.
Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., or Korro, is taking a temporary medical leave of absence.
Korro’s Board of Directors appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim principal financial officer
on February 5, 2025, the Company and Mr. Mattacchione agreed to extend the effective date of Mr. Mattacchione’s resignation to February 20, 2025
In connection with Ms. Chaibi’s appointment, Richard B. Leeds resigned as the Company’s Interim Chief Executive Officer, effective as of the Effective Date.
On February 10, 2025, Global Industrial Company (the “Company”) announced the appointment of Anesa Chaibi as Chief Executive Officer (principal executive officer) of the Company, effective February 17, 2025 (the “Effective Date”).
the Board of Directors elected Mr. Eric A. Clark to succeed Mr. Eddie Capel as President and Chief Executive Officer of the Company, to be effective February 12, 2025.
On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025
Ms. Romo will step down from that role
unanimously elected Tom Doxey to succeed Tammy Romo as Executive Vice President & Chief Financial Officer
On February 10, 2025, the Company announced the appointment of Lorenzo A. Flores as Senior Vice President, Chief Financial Officer (“CFO”) of the Company, effective February 10, 2025
On February 10, 2025, the Company terminated the employment of each of Jeffrey M. Soinski, the Company’s Chief Executive Officer and Nabeel Subainati, Vice President, Finance, effective as of February 10, 2025.
the Board appointed following officers and directors: Adam Clode, Chief Executive Officer
On February 3, 2025, Balu Balakrishnan notified the Company that he intends to retire from his position as president and chief executive officer.
On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.
On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.
Erin Day, 41, the Company’s Executive Vice President of Finance, will be acting Chief Financial Officer effective immediately.
Daniel J. Mathewes, President and Chief Financial Officer of Hilton Grand Vacations Inc. (the “Company”), informed the Company that he is taking a temporary leave of absence from his position at the Company for personal reasons, effective immediately.
Garett Rosenblum 51 Chief Financial Officer and Treasurer
Darren L. Richman is the Chief Executive Officer and President of Millrose.
approved the appointment of Mr. Blair Jordan as Chief Executive Officer of the Company (previously Mr. Jordan was Interim Chief Executive Officer of the Company)
On February 3, 2025, the Board appointed Farouq Tuweiq (“ Mr. Tuweiq ”) as the successor President and CEO of the Company, effective immediately following the 2025 Annual Meeting.
In light of Mr. Tuweiq’s upcoming elevation to the President and CEO role, it is anticipated that Mr. Tuweiq will vacate his current role as CFO / PFO concurrently with his assumption of the CEO role effective immediately following the 2025 Annual Meeting, with the Board having initiated a search process to identify a successor CFO / PFO for the Company.
On February 3, 2025, Michael S. Abrams, Chief Financial Officer and Treasurer of Arch Therapeutics, Inc. (the “Company”), resigned from his positions with the Company, effective immediately, and has waived any potential rights or claim to any financial obligations under his employment contract.
In connection with the Transaction Mr. Grimes also resigned as Chief Executive Officer of the Company.
appointed Philip G. Brace as the Chief Executive Officer and President of the Company and as a director, effective February 17, 2025
will step down from his roles as Chief Executive Officer and President of the Company as of the Transition Date
TamHao B. Nguyen has resigned from her position as Senior Vice President, Chief Financial Officer and Corporate Secretary of the Corporation and the Bank, effective February 21, 2025
Haryanto “Lee” Sunarto, the Treasurer and Vice President has agreed to also serve as Interim Chief Financial Officer effective February 22, 2025
Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.
On February 1, 2025, pursuant to, and subject to the terms of, the Vignola Transition Agreement, Mr. Vignola confirmed that his separation from employment was effective as of February 1, 2025 (the “Vignola Separation Date”) and resigned as of the Vignola Separation Date from all officer and director positions at the Company, the Subsidiary and any other subsidiary or affiliate.
Effective June 10, 2025, Mr. Malone shall be employed as the Company’s President and Chief Executive Officer (the “CEO Period”).
the officers of Merger Sub immediately prior to the Effective Time became the officers of the surviving corporation, effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Jeffery A Bedard as Chief Executive Officer, Nadeem Moiz as President, Chief Financial Officer and Chief Operating Officer, and Shellie L. Hammock as Executive Vice President, General Counsel and Secretary.
the officers of Merger Sub immediately prior to the Effective Time became the officers of the surviving corporation, effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Jeffery A Bedard as Chief Executive Officer, Nadeem Moiz as President, Chief Financial Officer and Chief Operating Officer, and Shellie L. Hammock as Executive Vice President, General Counsel and Secretary.
Effective as of and contingent upon the Retirement, the Company intends to appoint Christiane Ohlgart, age 57, to serve as Chief Financial Officer of the Company (including as its Principal Financial Officer).
On February 4, 2025, Keith Jensen, Fortinet’s Chief Financial Officer, age 66, notified the Company that he intends to retire on May 15, 2025
On February 6, 2025, the Board of Directors (the “Board”) of Escalade, Incorporated (“Escalade” or the “Company”) announced that Armin Boehm has agreed to become the Company’s new Chief Executive Officer and President.
On February 1, 2025, the Company appointed Srdjan (“Serge”) Tanjga, who served as Senior Vice President, Finance at MongoDB, Inc. (the “Company”), as the Company’s Interim Chief Financial Officer, effective February 1, 2025.
On January 31, 2025, Stephen D. Sheldon, chief financial officer and chief operational officer of PaxMedica, Inc., a Delaware corporation (the “Company”), provided notice of his resignation as an executive officer of the Company, effective immediately.
On January 31, 2025, the Board appointed Mr. Golden as CFO of the Company on a permanent basis.
On January 31, 2025, the Company terminated Jeff Clayborne, the prior Chief Financial Officer of the Company.
On January 31, 2025, the Company terminated Mark Buckley as Chief Executive Officer of the Company.
On February 3, 2025, the Board of Directors (the “Board”) of the Company appointed Chath Weerasinghe as the Company’s Chief Financial Officer and Chief Operating Officer, effective February 3, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.